These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 34043431)

  • 1. Adjuvant Tyrosine Kinase Inhibitors in Renal Cell Carcinoma: A Concluded Living Systematic Review and Meta-Analysis.
    Riaz IB; Siddiqi R; Islam M; He H; Riaz A; Asghar N; Naqvi SAA; Warner JL; Murad MH; Kohli M
    JCO Clin Cancer Inform; 2021 May; 5():588-599. PubMed ID: 34043431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant Tyrosine Kinase Inhibitors in Treatment of Renal Cell Carcinoma: A Meta-Analysis of Available Clinical Trials.
    Massari F; Di Nunno V; Mollica V; Graham J; Gatto L; Heng D
    Clin Genitourin Cancer; 2019 Apr; 17(2):e339-e344. PubMed ID: 30704796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant therapy with tyrosine kinase inhibitors for localized and locally advanced renal cell carcinoma: an updated systematic review and meta-analysis.
    Laukhtina E; Quhal F; Mori K; Sari Motlagh R; Pradere B; Schuettfort VM; Mostafaei H; Katayama S; Grossmann NС; Rajwa P; Resch I; Enikeev D; Karakiewicz PI; Shariat SF; Schmidinger M
    Urol Oncol; 2021 Nov; 39(11):764-773. PubMed ID: 34400065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-risk Surgically Resected Renal Cell Carcinoma: Is There a Role for Adjuvant VEGF-TKI Inhibitors?
    Fallara G; Bandini M; Larcher A; Pederzoli F; Karakiewicz P; Tian Z; Briganti A; Necchi A; Salonia A; Bertini R; Montorsi F; Bex A; Capitanio U
    Curr Probl Cancer; 2021 Dec; 45(6):100759. PubMed ID: 34130863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (TKIs) in Resected Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-analysis.
    Raphael J; Vincent M; Boldt G; Shah PS; Rodrigues G; Blanchette P
    Am J Clin Oncol; 2019 May; 42(5):440-445. PubMed ID: 30913091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pembrolizumab outperforms tyrosine kinase inhibitors as adjuvant treatment in patients with high-risk renal cell carcinoma after nephrectomy.
    Laukhtina E; Quhal F; Mori K; Sari Motlagh R; Rajwa P; Yanagisawa T; Mostafaei H; König F; Aydh A; Pradere B; Enikeev D; Karakiewicz PI; Schmidinger M; Shariat SF
    Eur Urol Oncol; 2022 Feb; 5(1):120-124. PubMed ID: 34992006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations.
    Tang W; Li X; Xie X; Sun X; Liu J; Zhang J; Wang C; Yu J; Xie P
    Lung Cancer; 2019 Oct; 136():6-14. PubMed ID: 31421260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant Therapy in High-Risk Renal Cell Cancer: A Systematic Review and Meta-analysis.
    Riaz IB; Faridi W; Husnain M; Malik SU; Sipra QUAR; Gondal FR; Xie H; Yadav S; Kohli M
    Mayo Clin Proc; 2019 Aug; 94(8):1524-1534. PubMed ID: 31303430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Living, Interactive Systematic Review and Network Meta-analysis of First-line Treatment of Metastatic Renal Cell Carcinoma.
    Riaz IB; He H; Ryu AJ; Siddiqi R; Naqvi SAA; Yao Y; Husnain M; Narasimhulu DM; Mathew J; Sipra QUAR; Vandvik PO; Joseph RW; Liu H; Wang Z; Herasevich V; Singh P; Hussain SA; Ho TH; Bryce AH; Pagliaro LC; Murad MH; Costello BA
    Eur Urol; 2021 Dec; 80(6):712-723. PubMed ID: 33824031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-epidermal growth factor receptor therapy for glioblastoma in adults.
    Lee A; Arasaratnam M; Chan DLH; Khasraw M; Howell VM; Wheeler H
    Cochrane Database Syst Rev; 2020 May; 5(5):CD013238. PubMed ID: 32395825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results.
    Motzer RJ; Ravaud A; Patard JJ; Pandha HS; George DJ; Patel A; Chang YH; Escudier B; Donskov F; Magheli A; Carteni G; Laguerre B; Tomczak P; Breza J; Gerletti P; Lechuga M; Lin X; Casey M; Serfass L; Pantuck AJ; Staehler M
    Eur Urol; 2018 Jan; 73(1):62-68. PubMed ID: 28967554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kidney Cancer Research Network of Canada consensus statement on the role of adjuvant therapy after nephrectomy for high-risk, non-metastatic renal cell carcinoma: A comprehensive analysis of the literature and meta-analysis of randomized controlled trials.
    Karakiewicz PI; Zaffuto E; Kapoor A; Basappa NS; Bjarnason GA; Blais N; Breau RH; Canil C; Drachenberg D; Hotte SJ; Jeldres C; Jewett MAS; Kassouf W; Kollmannsberger C; Lavallée LT; Maloni R; Patenaude F; Pouliot F; Reaume MN; Sabbagh R; Shayegan B; So A; Soulières D; Tanguay S; Wood L; Bandini M
    Can Urol Assoc J; 2018 Jun; 12(6):173-180. PubMed ID: 29877179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies.
    Ciccarese C; Iacovelli R; Brunelli M; Massari F; Bimbatti D; Fantinel E; De Marco V; Porcaro AB; Martignoni G; Artibani W; Tortora G
    Eur J Cancer; 2017 Sep; 83():237-246. PubMed ID: 28756136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patients with sarcomatoid renal cell carcinoma - re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors.
    Iacovelli R; Ciccarese C; Bria E; Bracarda S; Porta C; Procopio G; Tortora G
    Eur J Cancer; 2020 Sep; 136():195-203. PubMed ID: 32712550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of addition of VEGFR and EGFR-family oral small-molecule tyrosine kinase inhibitors to cytotoxic chemotherapy in solid cancers: a systematic review and meta-analysis of randomized controlled trials.
    Funakoshi T; Latif A; Galsky MD
    Cancer Treat Rev; 2014 Jun; 40(5):636-47. PubMed ID: 24629273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review.
    Nevitt SJ; Marson AG; Tudur Smith C
    Cochrane Database Syst Rev; 2019 Jul; 7(7):CD001911. PubMed ID: 31318037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of toxicity with immunotherapy-tyrosine kinase inhibitors for metastatic renal cell carcinoma: a meta-analysis of randomized controlled trials.
    Rizzo A; Mollica V; Santoni M; Rosellini M; Marchetti A; Massari F
    Future Oncol; 2022 Feb; 18(5):625-634. PubMed ID: 34927453
    [No Abstract]   [Full Text] [Related]  

  • 18. Evaluation of disease-free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: A trial-level meta-analysis.
    Harshman LC; Xie W; Moreira RB; Bossé D; Ruiz Ares GJ; Sweeney CJ; Choueiri TK
    Cancer; 2018 Mar; 124(5):925-933. PubMed ID: 29266178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
    Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ
    Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial.
    Powles T; Plimack ER; Soulières D; Waddell T; Stus V; Gafanov R; Nosov D; Pouliot F; Melichar B; Vynnychenko I; Azevedo SJ; Borchiellini D; McDermott RS; Bedke J; Tamada S; Yin L; Chen M; Molife LR; Atkins MB; Rini BI
    Lancet Oncol; 2020 Dec; 21(12):1563-1573. PubMed ID: 33284113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.